- €52.12m
- €59.58m
- €88.17m
Brief: Vita 34 FY revenues up 15 pct at 16.3 million euros
Brief: Vita 34 FY sales revenues up at 16.2 million euros
Brief: Vita 34 9-mth revenues up 16.9 pct to 12.0 million euros
Brief: Vita 34 expands its business in China
Brief: Vita 34 H1 revenue up 25 pct at 8.0 million euros
Brief: Vita 34 Q1 sales revenues up 24.2 pct to EUR 3.8 million
Brief: Vita 34 expects an EBITDA margin of 8 to 12 pct for 2016
Brief: Vita 34 FY operating revenues up 22.1 percent at 18.5 mln euros
Brief: Vita 34 FY operating revenues up 22.1 percent at 18.5 mln euros
Brief: Vita 34 9-month operating revenue up 4.9 pct at EUR 11.4 mln
Brief: Vita 34 appoints new CFO Falk Neukirch
Brief: Vita 34 takes over Danish StemCare Group
Brief: Vita 34 AG reports higher H1 revenue, profits
Brief: Vita 34 acquires 30 pct of Bio Save shares
Brief: Vita 34 Q1 EBITDA flat at 0.6 million euros
Brief: Vita 34 proposes dividend of 0.15 euros per share
Brief: Vita 34 preliminary FY 2014 sales revenues up to EUR 13.8 mln
Brief: Vita 34 enters into cooperative agreement with Baltic stem cell bank Imunolita
Brief: Vita 34 to take over all assets of Vivocell Biosolutions